N-[2-[(2-bromo-4,6-dinitrophenyl)azo]-5-(diethylamino)phenyl]acetamide

Acute Toxicity: dermal

Administrative data

Endpoint:

acute toxicity: dermal

Type of information:

experimental study

Adequacy of study:

key study

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

study well documented, meets generally accepted scientific principles, acceptable for assessment

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

1974

Report date:

1974

Materials and methods

Test guideline

Qualifier:

equivalent or similar to guideline

Guideline:

OECD Guideline 402 (Acute Dermal Toxicity)

GLP compliance:

no

Test type:

standard acute method

Limit test:

yes

Test material

Test material information

Constituent 1

Reference substance name:

2,2'-[[5-acetamide-4-[(2-bromo-4,6-dinitrophenyl)azo]-2-ethoxyphenyl]imino]diethyl diacetate

EC Number:

235-475-5

EC Name:

2,2'-[[5-acetamide-4-[(2-bromo-4,6-dinitrophenyl)azo]-2-ethoxyphenyl]imino]diethyl diacetate

Cas Number:

12239-34-8

Molecular formula:

C24H27BrN6O10

IUPAC Name:

({2-acetamido-3-[(2-bromo-4,6-dinitrophenyl)diazenyl]-5-ethoxyphenyl}imino)diethane-2,1-diyl diacetate

Test material form:

liquid

Details on test material:

Mablue S-2GLfl

Test animals

Species:

rat

Strain:

other: CFY

Sex:

male

Details on test animals or test system and environmental conditions:

Weight range: 244 to 264 g

Administration / exposure

Type of coverage:

occlusive

Vehicle:

unchanged (no vehicle)

Details on dermal exposure:

TEST SITE
- Area of exposure: dorso-lumbar region
- % coverage: 10% of the total body surface
- Type of wrap if used: aluminium foil

REMOVAL OF TEST SUBSTANCE
- Washing (if done): warm (40-50°C) dilute soap solution, rinsing in clean warm water
- Time after start of exposure: 24 h

Duration of exposure:

24 hours

Doses:

5 mL/kg bw

No. of animals per sex per dose:

10 male rats

Control animals:

yes

Remarks:

treated with water

Details on study design:

- Duration of observation period following administration: 14 d
- Frequency of observations: clinical signs daily; body weight weekly
- Necropsy of survivors performed: yes

Statistics:

NA

Results and discussion

Preliminary study:

NA

Effect levels

Key result

Sex:

not specified

Dose descriptor:

LD50

Effect level:

> 5 mL/kg bw

Mortality:

no deaths

Clinical signs:

other: slight lethargy and piloerection

Gross pathology:

congestion of the lungs ond pale or uneven col.ouration of the liver and kidneys. Five rats had haemorrhage of.the subcutaneous blood vessels of the treated areas.

Applicant's summary and conclusion

Interpretation of results:

GHS criteria not met

Conclusions:

Under the study conditions, acute dermal LD50 of the test substance in rats was determined to be greater than 5 mL/kg bw.

Executive summary:

A study was conducted to determine the acute dermal toxicity of the test substance according to a method equivalent to OECD Guideline 402. No mortality was observed in the treated rats. According to the study conditions, the acute dermal LD50 of the test substance was determined to be greater than 5 mL/kg bw (Davies, 1974).